BSX · 10-Q · 2026Q2 · Full report

Stock Repurchase Program

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 64 · Surprise 42 · Contradicted

On February 18, 2026, the Board increased Boston Scientific’s common-stock repurchase authorization by $4.0 billion, raising total authorization to $5.0 billion. Under an accelerated share repurchase agreement with JPMorgan entered on May 18, 2026, Boston Scientific paid $2.0 billion upfront, received approximately 30 million shares initially and approximately 10 million additional shares at final settlement on June 12, 2026. As of June 30, 2026, $3.0 billion remained available under the authorization, and future repurchases may be conducted through open-market, block, private or structured transactions depending on market conditions, regulatory requirements and other considerations.

Key facts

• On February 18, 2026 the Board approved a $4.000 billion increase to the existing repurchase authorization of $1.000 billion, increasing total repurchase authorization to $5.000 billion. source
• As of June 30, 2026, Boston Scientific had $3.000 billion remaining available under the share repurchase authorization. source
• On May 18, 2026 Boston Scientific entered into an accelerated share repurchase (ASR) agreement with JPMorgan; on May 19, 2026 it made an upfront payment of $2.000 billion and received an initial delivery of approximately 30 million shares (about 80% of transaction value), and final settlement on June 12, 2026 delivered approximately 10 million additional shares. source

Impact estimates